Abstract: Fibrocytes, which are bone marrow-derived collagen-producing cells, were reported to play a role in the pathogenesis of pulmonary fibrosis. However, their function in pulmonary fibrosis is unclear. We analyzed their function compared with that of monocytes and localization in fibrotic tissues in patients with idiopathic pulmonary fibrosis (IPF). We compared the gene expression profile of monocyte-derived fibrocytes with that of monocytes by microarray analysis. Proliferation and differentiation into myofibroblasts were examined by \(^{3}\)H-thymidine incorporation assay and Western blotting. We measured the level of growth factors in the culture supernatant of fibrocytes by ELISA. The localization of fibrocytes in lung tissues of patients with IPF was determined by immunofluorescence staining. Compared with monocytes, fibrocytes had higher expression of extracellular matrix- and growth factor-encoding genes, including PDGF-B, FGF-2 and VEGF-B. Although fibrocytes did not proliferate in response to PDGF, co-culture of fibrocytes stimulated the growth of lung fibroblasts through the production of PDGF-BB. In the lung of IPF patients, CD45\(^+\)Collagen-I\(^+\)FSP-1\(^+\) cells, which have a similar phenotype to fibrocytes, were detected and co-stained with anti-PDGF antibody. This study suggested that fibrocytes function in pulmonary fibrosis partly by producing PDGF in the lungs of IPF patients. J. Med. Invest. 67:102-112, February, 2020

Keywords: fibrocyte, fibroblast, idiopathic pulmonary fibrosis, PDGF

INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal disease of the lungs, characterized by the proliferation of fibroblasts and deposition of extracellular matrix (1, 2). Recent studies on the molecular pathogenesis in IPF demonstrated novel lung fibroblasts from other origins, including bone-marrow cells, alveolar epithelial cells, endothelial cells, pleural cells and pericytes, in addition to resident fibroblasts (3-9).

Fibrocytes are defined as bone marrow-derived and collagen-expressing cells, which constitute approximately 0.5% of the peripheral blood leukocyte population, exhibiting an adherent spindle shape in culture (10, 11). Therefore, fibrocytes express markers of hematopoietic cells (CD34), leukocytes (CD11b, CD13 and CD45) and the extracellular matrix (collagens I and III, and fibronectin) (11-13). A number of studies have reported the potential for bone marrow-derived circulating fibrocytes to enter tissues following injury, leading to lung fibrosis (3, 4, 14-19). In addition, a clinical trial of pentraxin-2, for IPF, which inhibits the generation of fibrocytes, was performed and reported significant anti-fibrotic effects (20, 21).

However, the role of fibrocytes in tissues remains unclear. Kleaveland et al. reported that the production of collagen by fibrocytes did not lead to pulmonary fibrosis in the Vav-Cre transgenic mice with specific deletion of the collagen Ia1 gene in hematopoietic cells (22), although fibrocytes are expected to be a source of lung fibroblasts.

We previously reported that fibrocytes have the ability to produce growth factors, and their functions are regulated by antifibrotic agents such as imatinib and nintedanib (23, 24). Garcia et al. found that co-culture of fibrocytes with lung fibroblasts increased the expression of collagen Ia1 and alfa-smooth muscle actin (SMA), and levels of chemokines and growth factors in fibroblasts (25). In the present study, to characterize the function of fibrocytes, we compared the gene expression profile of human monocyte-derived fibrocytes with that of monocytes, demonstrating the pro-fibrotic phenotype of fibrocytes. We also examined several functions, including growth and differentiation to myofibroblasts, and the production of growth factors in vitro and in lung tissues of patients with IPF.

MATERIALS AND METHODS

Ethics statement

This study was approved by the institutional review board of Tokushima University Hospital (Approval Numbers: 2919, 2920), and conformed to the Declaration of Helsinki.

Isolation of human monocytes and fibrocytes

Peripheral blood mononuclear cells (PBMCs) were isolated from human peripheral blood using Ficoll density centrifugation. Human peripheral blood monocytes were purified from PBMCs by magnetic beads for CD14 (23). PBMCs from the same donor were used to isolate fibrocytes according to previously published methods (23), and were then cultured in the fibronectin-coated flasks including DMEM (Dulbecco’s Modified, Eagle Medium) (Grand Island Biological Co. Grand Island, NY, USA) supplemented with 20% fetal bovine serum (FBS) for 7 days.
The adherent cells were harvested using 0.125% trypsin. We used immunomagnetic selection to deplete B lymphocytes (anti-CD19; Miltenyi Biotech, Auburn, CA, USA), T lymphocytes (anti-CD3; Miltenyi Biotech) and monocytes/macrophages (anti-CD14; Miltenyi Biotech) from our crude fibrocyte preparation. The trypsinized cells were stained with anti-CD19, CD3 and CD14 antibodies coupled to magnetic beads. Labeled cells were then sorted by binding the cell population to positive-selection columns using Auto Macs (Miltenyi Biotech).

**Total RNA isolation and qPCR**

Total cellular RNA was isolated using RNeasy Mini kits and RNase-free DNase kits (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocols. RNA was reversely transcribed on a Takara PCR thermal cycler Dico (Takara Bio., Inc., Kyoto, Japan) using the High Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster City, CA, USA) and SYBR® Premix Ex Taq™ (Perfect Real Time) (Takara Bio Inc.) following the manufacturer's instructions. The expression of TGF-β1, PDGF-B, FGF-2 and the housekeeping gene human RPL27 was measured by quantitative PCR analysis on an ABI 7700 Sequence Detection system (Applied Biosystems) using the following commercially available sets of primers and fluorogenic probes: (TaqMan® Gene Expression Assay® products): TGF-β1, Hs00966522_ml; PDGF-B, Hs00966522_ml; FGF-2, Hs0026645_ml. The quantitative PCR experiments were performed in triplicate, and the relative expression levels were calculated based on the comparative Ct method.

**Microarray analysis**

The relative purity of the RNA was measured using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) (26). One hundred and thirty ng of total RNA was amplified and labeled using the Agilent Low Input Quick Amp Labeling Kit, One-Color (5190-2305), and labeled RNA was hybridized with the Human Gene expression 4x44K v2 Microarray Kit (G4845A). Agilent Feature Extraction Image Analysis Software (Version 10.7.3) was used to extract data from raw microarray image files. Data visualization and analysis were performed using GeneSpring GX (Version 12.1) software.

**Cell cultures and fibroblast isolation**

MRC5 fibroblasts were purchased from ATCC (Masassas, VA, USA). Human IPF-fibroblast cells were generated from biopsy samples from patients with IPF (24). 3H-Thymidine uptake assay

The lung fibroblasts or fibrocytes were added to a 96-well plate at 2x10³ cells per well. The cells (50-70% confluent) were treated with PDGF-BB (0, 1 or 10 ng/ml) for 48 hours with or without irradiated fibroblasts (50 Gy) or fibrocytes (55 Gy) at the indicated cell number. These cells were labeled with 3H-thymidine deoxyribose (TdR) (6.7 Ci/mmol ; Amersham Corp., Arlington Heights, IL, USA) at 1 μCi/well for the final 16 hours. The cells were harvested on glass fibers in a cell harvester, MASHII (Labo Science Co., Tokyo, Japan), and the incorporation of 3H-TdR was measured using a liquid scintillation counter (27). In some experiments, the supernatant of fibroblasts was added and neutralizing antibodies (2 μg/ml) for FGF-2, PDGF-BB, and TGF-β (R&D Systems, Minneapolis, MN, USA) was used. Cell proliferation was evaluated by assaysing the incorporation of 3H-TdR. The experiments were performed in triplicate cultures.

**ELISA**

The human fibrocytes (1x10⁶) and monocytes (1x10⁶) from same donor were cultured in 1 ml of fresh culture medium (DMEM with 0.1% FBS). After incubation for 48 h, the culture media were harvested and centrifuged, and the supernatants were stored at -80°C until used as the culture supernatant. For human growth factors, their concentrations were quantified using ELISA kits (R&D Systems) following the manufacturers' instructions. The minimum and maximum detectable protein levels were TGF-β1 (31.2-2000 pg/ml), PDGF-BB (31.2-2000 pg/ml) and FGF-2 (10-640 pg/ml). Data are presented as the mean ± SEM in each group. Data are representative of three separate experiments.

**Western blot**

Human lung fibroblasts and fibrocytes were cultured in DMEM supplemented with 0.1% FBS with or without 5 ng/ml of TGF-β1. The cells were transferred quickly to ice and lysed in RIPA buffer (10 mM TrisHCl pH 7.4, 1% NP40, 0.1% sodium deoxycholate, 0.1% SDS, 0.15 mM NaCl, 1 mM EDTA and 10 μg/ml of aprotonin) and 1 mM phenylmethylsulfonyl fluoride (PMSF). The protein concentration was measured by protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Twenty micograms of total cell extract protein was suspended in 2 x Laemmli sample buffer (Bio-Rad Laboratories). These samples were boiled for 5 minutes and electrophoresed on 4-10% NuPAGE Bis-Tris Mini gels (at 200 Voltage for 40 min). Then, proteins were electroblotted onto iBlot™ gel Transfer polyvinylidene difluoride (PVDF) membranes (Life Technologies, Carlsbad, CA, USA). The membranes were blocked with 0.2% non-fat milk/Tris-buffered saline-Tween 20° solution in blot holders (SNAP i.d. TM Protein Detection System, Millipore, Billerica, MA, USA). Transferred membranes were incubated with anti-alpha-smooth muscle actin antibody (Sigma-Aldrich, St. Louis, MO, USA) at 4°C overnight, followed by incubation for 60 min at room temperature with goat-anti mouse IgG horseradish peroxidase-conjugated IgG (Cayman Chemical, Ann Arbor, MI, USA). Transferred membranes were incubated with biotin-conjugated anti-collagen-type 1 antibody (Rockland, Gilbertsville, PA, USA) at 4°C overnight, followed by incubation for 60 min at room temperature with streptavidin horseradish peroxidase-conjugated secondary antibody (Rockland). Transferred membranes were incubated with anti-beta-actin antibody (GenScript, Piscataway, NJ, USA) at 4°C overnight, followed by incubation for 60 min at room temperature with goat-anti mouse IgG horseradish peroxidase (Cayman Chemical). Protein-antibody conjugates were then developed using enhanced chemiluminescent substrate (Thermo Scientific Inc.; Rockford, IL). The immunoreactive bands were read under a luminescent image analyzer (Las-4000 mini; Fuji Film, Tokyo, Japan).

**Immunofluorescence staining**

The lungs were fixed in 10% buffered formalin and embedded in paraffin. Sections (3 to 4 μm) were stained with hematoxylin and eosin. Paraffin-embedded lung sections were stained to detect fibrocytes using the following antibodies: anti-C4D45 antibody (Cell Signaling Tech, Danvers, MA, USA), secondary antibody: streptavidin-FITC (eBioscience, Ireland, UK); anti-collagen-type 1 antibody (Abcam; Cambridge, UK) and anti-FSP-1 antibody (Thermo Fisher scientific Inc.), respectively.

For triple staining, to detect PDGF-BB in fibrocytes, the following antibodies were used: anti-human FSP-1 antibody (Thermo Fisher scientific Inc.), anti-human CXCR4 antibody...
S. Abe, et al. Fibrocytes activate fibroblasts by PDGF.

(Abcam) and anti-human PDGF-BB antibody (Novus biological, Litteleton, CO, USA), and the fluorescent secondary antibodies conjugated with Alexa Flour 488, 594 or 647 (Thermo Fisher scientific Inc.), respectively. To detect proliferating cells, the section was first stained with anti-Ki-67 antibody (Agilent Technologies) followed by the secondary antibody conjugated with Alexa Flour 594 were used. Images were taken using a confocal laser scanning microscope, A1 system (Nikon, Tokyo, Japan).

Statistical Analysis

The results were analyzed using the Mann-Whitney test for comparison between any two groups, and by nonparametric equivalents of ANOVA for multiple comparisons. \( p < 0.05 \) was considered to indicate significance.

RESULTS

Comparison of the gene expression profile of monocyte-derived fibrocytes and monocytes

First, we compared the gene expression profile of monocyte-derived fibrocytes and monocytes in paired samples from the same donor by microarray analysis. When we analyzed 9668 genes, we found 4062 genes that were upregulated in fibrocytes compared with monocytes, whereas 5606 genes were down-regulated in fibrocytes compared with monocytes (Figure 1A). As shown in the heat-map in Figure 1B, gene expression in fibrocytes from four donors was homogenous and different from that in monocytes.

Focusing on several groups of genes, among cytokines, genes for those, such as colony stimulating factor (CSF) 2, interleukin (IL) 13, CSF1, IL-1 and IFN-\( \gamma \), were strongly up-regulated in fibrocytes compared with monocytes, whereas the CSF3R gene was down-regulated in fibrocytes (Table 1). Among growth factors, genes for those, such as platelet-derived growth factor (PDGF) RA, fibroblast growth factor (FGF) R1 and vascular endothelial growth factor (VEGF) B, were strongly up-regulated in fibrocytes, whereas the hepatocyte growth factor (HGF) gene was significantly down-regulated in fibrocytes (Table 2). Among chemokines, several CC chemokine ligand (CCL) genes, such as CCL18, CCL7, CCL2 and CCL13, were up-regulated in fibrocytes (Table 3). Regarding the extra-cellular matrix (ECM), several collagen genes, such as collagen Vla1, Ia1 and VIa2, and integrins such as a3, b5, b8 and a6, were strongly up-regulated in fibrocytes (Table 4). In addition, many matrix-metallopeptidases (MMPs), such as MMP 7, 9, 2 and 14, were significantly up-regulated in fibrocytes (Table 5).

Higher expression of growth factors in fibrocytes than in monocytes

Gene expression analysis revealed the profibrotic phenotype of fibrocytes because genes for growth factors, ECM and MMPs were strongly up-regulated in fibrocytes. Therefore, we focused on the production of growth factors by fibrocytes. As shown in Figure 2, fibrocytes had higher expression of PDGF-B and FGF-2, but not TGF-\( \beta \), at the mRNA and protein levels.

Ability of fibrocytes to grow and differentiate into myofibroblasts

Next, we examined the growth ability of fibrocytes in response to PDGF-BB and co-culture with fibroblasts. To assess the \( ^{3} \text{H}-\text{TdR} \) uptake of fibrocytes, fibroblasts were irradiated and added into fibrocyte cultures (Figure 3A). As a result, the fibrocytes did not proliferate in response to PDGF-BB even in the co-culture with fibroblasts. On the other hand, fibrocytes were irradiated and co-cultured with fibroblasts. As shown in Figure 3B, fibroblasts had the ability to proliferate after stimulation by PDGF-BB, and co-culture with fibrocytes significantly increased their proliferation in a fibrocyte-dependent manner. These
Table 1  Selected up- and down-regulated genes related to cytokines and their receptors in fibrocytes in comparison with monocytes

| Gene symbol | Probe name | Gene name                        | P      | Fold change |
|-------------|------------|----------------------------------|--------|-------------|
| (1)Up       |            |                                  |        |             |
| CSF2        | A_23_P133408 | colony stimulating factor 2      | 6E-05  | 101.4       |
| IL13        | A_23_P251031 | interleukin 13                   | 0.004  | 20.88       |
| CSF1        | A_33_P3354035 | colony stimulating factor 1      | 4E-06  | 13.67       |
| IL2RA       | A_24_P230863  | interleukin 2 receptor, alpha    | 0.002  | 13.67       |
| IL1A        | A_23_P72096   | interleukin 1, alpha             | 0.011  | 12.24       |
| IFNG        | A_23_P151294  | interferon, gamma                | 0.002  | 11.12       |
| IL22RA2     | A_33_P3422124 | interleukin 22 receptor, alpha 2 | 0.024  | 8.402       |
| IL17RB      | A_23_P167479  | interleukin 17 receptor B        | 0.002  | 8.086       |
| IL17C       | A_33_P3339625 | interleukin 17C                  | 0.001  | 7.402       |
| IL2RG       | A_23_P148473  | interleukin 2 receptor, gamma    | 6E-06  | 5.238       |
| (2)Down     |            |                                  |        |             |
| CSF3R       | A_33_P3381262 | colony stimulating factor 3 receptor | 2E-05  | -11.2       |
| IL1B        | A_23_P79518   | interleukin 1, beta              | 0.04   | -7.9        |
| CSF2RA      | A_33_P3232688 | colony stimulating factor 2 receptor, alpha | 7E-04  | -5.46       |
| IL6R        | A_33_P3288844 | interleukin 6 receptor           | 1E-06  | -4.82       |
| IL11RA      | A_23_P71867   | interleukin 11 receptor, alpha   | 7E-04  | -4.48       |
| IL19        | A_23_P35092   | interleukin 19                   | 0.027  | -3.25       |
| IL17A       | A_23_P332820  | interleukin 17A                  | 0.002  | -2.53       |
| IL12A       | A_23_P91943   | interleukin 12A                  | 0.039  | -2.52       |
| IFNA4       | A_24_P403459  | interferon, alpha 4              | 0.006  | -2.39       |
| IL33        | A_23_P31945   | interleukin 33                   | 0.001  | -2.32       |

Table 2  Selected up- and down-regulated genes related to growth factors and their receptors in fibrocytes in comparison with monocytes

| Gene symbol | Probe name | Gene name                                      | P      | Fold change |
|-------------|------------|-----------------------------------------------|--------|-------------|
| (1)Up       |            |                                               |        |             |
| PDGFR1      | A_23_P300033 | platelet-derived growth factor receptor, alpha polypeptide | 4E-04  | 27.73       |
| FGFR1       | A_23_P372923 | fibroblast growth factor receptor 1           | 2E-04  | 17.24       |
| VEGFB       | A_23_P1594   | vascular endothelial growth factor B          | 3E-05  | 13.94       |
| IGFA        | A_23_P150609 | insulin-like growth factor 2                  | 0.001  | 6.378       |
| TGFBR2      | A_24_P402438 | transforming growth factor, beta 2            | 0.034  | 3.601       |
| PDGFB       | A_24_P339944 | platelet-derived growth factor beta polypeptide | 0.172  | 3.558       |
| IGFR2       | A_23_P334021 | insulin-like growth factor 2 receptor         | 8E-04  | 3.078       |
| TGFBR3      | A_23_P200780 | transforming growth factor, beta receptor III  | 0.025  | 2.523       |
| FGFB        | A_33_P3257027 | fibroblast growth factor 7                  | 0.005  | 2.187       |
| PDGFB       | A_23_P421401 | platelet-derived growth factor receptor, beta polypeptide | 0.017  | 1.925       |
| (2)Down     |            |                                               |        |             |
| HGF         | A_33_P3276713 | Hepatocyte growth factor                   | 3E-04  | -16         |
| TGFBR2      | A_33_P3313825 | transforming growth factor, beta receptor II  | 0.009  | -4.01       |
| FGFB        | A_33_P3380797 | fibroblast growth factor 3                 | 0.004  | -2.67       |
| IGFR1       | A_23_P417282 | insulin-like growth factor 2 receptor        | 0.003  | -2.38       |
| TGFBR3      | A_23_P88404  | transforming growth factor, beta              | 0.002  | -2.14       |
Table 3  Selected up- and down-regulated genes related to chemokines and their receptors in fibrocytes in comparison with monocytes

| Gene symbol | Probe name | Gene name | P     | Fold change |
|-------------|------------|-----------|-------|-------------|
| CCL18       | A_23_P55270 | chemokine (C-C motif) ligand 18 | 5E-06 | 3659        |
| CCL7        | A_23_P78037 | chemokine (C-C motif) ligand 7 | 3E-06 | 969.7       |
| CCL2        | A_23_P89431 | chemokine (C-C motif) ligand 2 | 3E-05 | 252.9       |
| CCL13       | A_24_P125335 | chemokine (C-C motif) ligand 13 | 0.005 | 248.8       |
| CXCL9       | A_24_P18452 | chemokine (C-X-C motif) ligand 9 | 0.001 | 69.63       |
| CCL8        | A_23_P207456 | chemokine (C-C motif) ligand 8 | 2E-04 | 68.64       |
| CCL22       | A_24_P313418 | chemokine (C-C motif) ligand 22 | 0.005 | 47.8        |
| CCL17       | A_23_P26325 | chemokine (C-C motif) ligand 17 | 0.015 | 36.59       |
| CCL1        | A_23_P49759 | chemokine (C-C motif) ligand 1 | 0.019 | 22.96       |
| CCL23       | A_24_P133905 | chemokine (C-C motif) ligand 23 | 0.006 | 15.28       |
| CXCL11      | A_23_P125278 | chemokine (C-X-C motif) ligand 11 | 0.082 | 11.56       |
| CXCL16      | A_33_P351249 | chemokine (C-X-C motif) ligand 16 | 9E-06 | 7.065       |
| CCR5        | A_33_P3395595 | chemokine (C-C motif) receptor 5 | 0.003 | 6,583       |
| CCL5        | A_23_P152838 | chemokine (C-C motif) ligand 5 | 0.019 | 3.097       |

(2)Down

| Gene symbol | Probe name | Gene name | P     | Fold change |
|-------------|------------|-----------|-------|-------------|
| CCR2        | A_23_P212354 | chemokine (C-C motif) receptor 2 | 0.006 | -69.02      |
| CCR9        | A_33_P3395595 | chemokine (C-C motif) receptor 9 | 0.001 | -12.17      |
| CCR3        | A_23_P250302 | chemokine (C-C motif) receptor 3 | 0.019 | -7.036      |
| CXCL14      | A_33_P3590259 | chemokine (C-X-C motif) ligand 14 | 8E-04 | -2.784      |
| CXCL12      | A_33_P3372840 | chemokine (C-X-C motif) ligand 12 | 0.004 | -2.691      |
| CCL21       | A_33_P3273623 | chemokine (C-C motif) ligand 21 | 0.01  | -2.291      |

Table 4  Selected up- and down-regulated genes related to the extracellular matrix and cell adhesion molecules in fibrocytes in comparison with monocytes

| Gene symbol | Probe name | Gene name | P     | Fold change |
|-------------|------------|-----------|-------|-------------|
| COL6A1      | A_32_P32254 | collagen, type VI, alpha 1 | 0    | 118         |
| COL1A1      | A_33_P3304668 | collagen, type I, alpha 1 | 3E-04 | 34.28       |
| ITGA3       | A_23_P55231 | integrin, alpha 3 | 3E-04 | 32.18       |
| ITGB5       | A_23_P166633 | integrin, beta 5 | 0.002 | 20.26       |
| ITGB8       | A_24_P759477 | integrin, beta 8 | 2E-04 | 19.91       |
| COL6A2      | A_23_P310956 | collagen, type VI, alpha 2 | 3E-06 | 19.64       |
| ITGA6       | A_33_P3231447 | integrin, alpha 6 | 4E-04 | 16.02       |
| COL22A1     | A_32_P405759 | collagen, type XXII, alpha 1 | 0.004 | 13.76       |
| COL5A2      | A_33_P3297930 | collagen, type VIII, alpha 2 | 7E-06 | 10.24       |
| ITGAV       | A_23_P50907 | integrin, alpha V | 2E-05 | 4.295       |
| ITGA7       | A_23_P128084 | integrin, alpha 7 | 0.009 | 3.892       |
| ITGA11      | A_23_P206022 | integrin, alpha 11 | 0.004 | 2.922       |

(2)Down

| Gene symbol | Probe name | Gene name | P     | Fold change |
|-------------|------------|-----------|-------|-------------|
| ITGA4       | A_33_P3224887 | integrin, alpha 4 | 5E-05 | -10.38      |
| COL4A4      | A_33_P3227400 | collagen, type IV, alpha 4 | 0.001 | -9.755      |
| COL18A1     | A_23_P211212 | collagen, type XVIII, alpha 1 | 1E-04 | -4.695      |
| COL4A1      | A_23_P65240 | collagen, type IV, alpha 1 | 0.002 | -3.795      |
| ITGA9       | A_23_P232193 | integrin, alpha 9 | 0.005 | -2.113      |
| COL27A1     | A_33_P3413168 | collagen, type XXVII, alpha 1 | 0.004 | -2.021      |
Table 5  Selected up- and down-regulated genes related to matrix metalloproteases and their inhibitors in fibrocytes in comparison with monocytes

| Gene symbol | Probe name    | Gene name                  | P     | Fold change |
|-------------|---------------|----------------------------|-------|-------------|
| (1)Up       |               |                            |       |             |
| MMP7        | A_23_P52761   | matrix metallopeptidase 7  | 0.04  | 331.3       |
| MMP9        | A_23_P40174   | matrix metallopeptidase 9  | 3E-04 | 239.4       |
| TIMP3       | A_23_P399078  | TIMP metallopeptidase inhibitor 3 | 3E-04 | 154.4       |
| MMP2        | A_33_P3237135 | matrix metallopeptidase 2  | 0.002 | 47.49       |
| MMP14       | A_24_P82106   | matrix metallopeptidase 14 | 4E-08 | 47.15       |
| TIMP4       | A_32_P70315   | TIMP metallopeptidase inhibitor 4 | 2E-04 | 41.67       |
| MMP12       | A_23_P150316  | matrix metallopeptidase 12 | 0.087 | 19.89       |
| MMP1        | A_23_P1691    | matrix metallopeptidase 1  | 0.01  | 16.63       |
| MMP19       | A_23_P203888  | matrix metallopeptidase 19 | 0.001 | 9.483       |
| MMP24       | A_33_P3498331 | matrix metallopeptidase 24 | 0.016 | 2.042       |
| (2)Down     |               |                            |       |             |
| MMP23B      | A_23_P4058    | matrix metallopeptidase 23B | 0.032 | -4.739      |
| MMP11       | A_23_P57417   | matrix metallopeptidase 11 | 0.006 | -3.633      |

Figure 2  Expression of growth factors in fibrocytes compared with that in monocytes. Expression of TGF-β, PDGF-B and FGF-2 was examined by qPCR (A) and ELISA (B). The experiments were performed as described in Materials and Methods. Expression levels of PDGF-B and FGF-2 were significantly higher in fibrocytes than in monocytes. Similar results were obtained in at least three independent experiments. *p < 0.01 vs monocytes. **p < 0.005 vs monocytes.
results suggest that fibrocytes can increase the proliferation of fibroblasts.

The supernatant of fibrocytes also stimulated 3H-TdR uptake by fibroblasts (Figure 3C and 3D). Treatment with anti-PDGF-BB antibody significantly reduced the fibrocyte-mediated increase in the growth of lung fibroblasts from MRC5 and IPF patients (Figure 3C and 3D). These data suggest that fibrocytes can stimulate the growth of fibroblasts through PDGF-BB production.

Next we examined the ability of fibrocytes to differentiate into myofibroblasts, which are believed to be activated fibroblasts (Figure 4). In this experiment, MRC5 fibroblasts and fibrocytes were cultured in the medium containing transforming growth factor-β (TGF-β) for three weeks. As shown in Figure 4, fibroblasts highly expressed both α-SMA and collagen I, and their expression further increased during the culture. However, α-SMA was not detected in fibrocytes and its expression did not increase during the culture (Figure 4A). In addition, the expression of collagen I was significantly lower in fibrocytes than in fibroblasts, and it also did not increase during the culture (Figure 4B).

**Figure 3** Fibrocytes increase the growth of lung fibroblasts through PDGF-BB production. The proliferation of human fibrocytes (A) or lung fibroblasts MRC5 (B) was examined by 3H-TdR uptake assay. A: Fibrocytes were co-cultured with the indicated number of irradiated fibroblasts with or without PDGF-BB. B: MRC5 cells were co-cultured with the indicated number of irradiated fibrocytes with or without PDGF-BB. *p < 0.05 vs no fibrocytes. **p < 0.01 vs no fibrocytes. C: The supernatant of fibrocytes was harvested and added to the culture of MRC5 cells in the presence (2 μg/ml) of anti-FGF-2, PDGF-BB and TGF-β neutralizing antibodies or control IgG. *p < 0.01 vs control IgG. D: The supernatant of fibrocytes was harvested and added to the culture of IPF fibroblasts in the presence of anti-FGF-2, PDGF-BB and TGF-β neutralizing antibodies or control IgG. Similar results were obtained in at least three independent experiments. *p < 0.05 vs control IgG. **p < 0.01 vs control IgG.

**Figure 4** Fibrocytes have lower ability to proliferate and differentiate into myofibroblasts. MRC5 cells and human fibrocytes were cultured in medium containing 5 ng/ml of TGF-β until three weeks. Their cell lysates were harvested weekly and the expression of α-SMA and collagen-I was examined by Western blotting as described in Materials and Methods. The data is the representative of three independent experiments which show the similar results.
Immunostaining of fibrocytes in lung tissues of patients with IPF

To detect fibrocytes in lung tissues of patients with IPF, we performed double and triple staining using several fibrocyte markers such as CD45, collagen I, CXCR4 and FSP-1. As shown in Figure 5A, fibrocytes positive for CD45, collagen I and FSP-1 were detected in the fibrotic areas in lung tissues of patients with IPF. In addition, fibrocytes were found to express PDGF-BB (Figure 5B). On analysis of proliferating cells using anti-Ki67 antibody, most of the positive cells were negative for CD45, although a few cells were positive for both CD45 and Ki67 (Figure 6).

DISCUSSION

In the present study, we examined the gene expression profile of monocyte-derived fibrocytes in comparison with that of monocytes. The fibrocytes were found to strongly express genes related to pulmonary fibrosis such as those for ECM, MMPs, profibrotic growth factors and cytokines. Although fibrocytes did not proliferate in response to PDGF-BB or differentiate into myofibroblasts in response to TGF-β, they have the ability to stimulate the growth of fibroblasts through PDGF-BB production. In lung tissues of patients with IPF, fibrocytes expressed PDGF-BB.

Figure 5  Immunofluorescence analysis of human fibrocytes in lung tissues from IPF patients. A: Triple staining using antibodies against CD45 (green), FSP-1 (red) and collagen-I (purple). The triple-positive cells were detected in the fibrotic area in the lung tissues of patients with IPF (arrowhead). DAPI: blue. B: Triple staining using antibodies against FSP-1 (green), CXCR4 (red) and PDGF-BB (purple). The triple-positive cells were detected in the fibrotic area in the lung tissues of patients with IPF (arrowhead). DAPI: blue. Scale bars: 50 μm.
Fibrocytes were originally thought to be one of the origins of fibroblasts (3, 4). However, the expression level of collagen was much lower than that in fibroblasts (12, 22, 28). In addition, it has been demonstrated that the production of collagen by bone marrow-derived cells, including fibrocytes, does not lead to pulmonary fibrosis (22, 29). Therefore, other roles of fibrocytes except ECM production have been expected.

In the present study, we demonstrated the characteristic gene expression profile of fibrocytes, which included the preferential expression of genes related to fibrogenesis, such as ECM, MMPs, profibrotic growth factors and cytokines. These data are partly consistent with previous reports (24, 25, 30, 31), and they comprehensively confirmed the pro-fibrotic phenotype of fibrocytes. Among the genes increased in fibrocytes, we focused on the genes encoding growth factors. As one role of fibrocytes, Garcia et al. reported that co-culture of fibrocytes from patients with hypersensitivity pneumonitis (HP) increased the expression of collagen Iα1 and α-SMA by lung fibroblasts, possibly through the production of TGF-β (25). This study suggested that fibrocytes promote the differentiation of fibroblasts into myofibroblasts via paracrine effects. In the present study, we found that fibrocytes promoted the growth of fibroblasts through PDGF-BB production. In our experiments, the supernatant of fibrocyte culture did not increase the expression of collagen or α-SMA (data not shown). The reason for the discrepancy is not clear, but of fibroblasts it may be due to the different experimental conditions.

It remains difficult to clearly detect fibrocytes in human lung tissues because several markers, including CD45 and collagen type I, are required to identify them. In the present study, we found fibrocytes in lung tissues of IPF patients by double or triple staining. In addition, growth factor, including PDGF-BB, were α-stained with other fibrocyte markers, suggesting that fibrocytes existing in fibrotic lung tissues produce PDGF-BB.

Human fibrocytes did not differentiate into myofibroblasts in response to TGF-β in the present study. Phillips et al. reported α-SMA expression in up to 30% of human fibrocytes after culturing for 28-35 days (4). Several previous reports stated that murine bone marrow-derived fibrocytes do not express α-SMA (5, 32). These studies suggested the poor ability of fibrocytes to differentiate into myofibroblasts. Regarding the proliferative activity of fibrocytes, Madala et al. reported the marked proliferation of murine fibrocytes harvested from TGF-α transgenic mice (30). In the present study, human fibrocytes did not exhibit growth by stimulation with PDGF-BB. The poor growth activity compared with that of fibroblasts is consistent with the previous report (14). However, recent studies reported the proliferative activity of fibrocytes in response to CCL2, IL-33 and IL-34, although the levels were low (33-35). Further studies regarding the growth of fibrocytes are required.

On the other hand, fibrocytes increased the proliferation of fibroblasts through PDGF-BB production in vitro. Furthermore, the Ki67-positive proliferating cells in IPF lung tissues were mainly found among the CD45-negative cell population, which likely included fibroblasts, and epithelial and endothelial cells. This suggests that fibrocytes play a role in stimulating the growth of resident fibroblasts in the fibrotic lung tissues.

Targeted therapy of fibrocytes and fibrotic macrophages using pentraxin-2 has been investigated in a clinical trial for patients with IPF (20, 21). However, further analysis of the function of fibrocytes is needed to develop novel therapies for IPF by targeting them.
ACKNOWLEDGEMENT

We thank Ms. Tomoko Oka for her technical assistance, and the members of Nishioka lab for their technical advice and useful discussion.

This study was partly supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant Number JP16H0530910) and a grant from the Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases (Y.N.; Code Number 0000025921).

REFERENCES

1. Richeldi L, Collard HR, Jones MG: Idiopathic pulmonary fibrosis. Lancet 389: 1942-1952, 2017.

2. Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L: Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res 19: 32, 2018.

3. Hashimoto N, Jin H, Liu T, Chenase SW, Phan SH: Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 113: 243-252, 2004.

4. Phillips JD, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM: Circulating fibrocytes traffic to the lungs in response to CXCR12 and mediate fibrosis. J Clin Invest 114: 438-446, 2004.

5. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Altemeier WA, Gharib SA, Schnapp LM, Duffield JS: Role of pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro. Am J Respir Cell Mol Biol 29: 243-252, 2003.

6. Kim KK, Kugler MC, Walters PJ, Robillard L, Galvez MG, Brunwell AN, Sheppard D, Chapman HA: Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 103: 13180-13185, 2006.

7. Nasreen N, Mohammed KA, Mubarak KK, Baz MA, Akindipe OA, Fernandez-Bussy S, Antony VB: Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro. Am J Physiol Lung Cell Mol Physiol 297: L115-124, 2009.

8. Hashimoto N, Phan SH, Minamizaki K, Matsuo M, Nakashima H, Kawabe T, Shimokata K, Hasegawa Y: Endothelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 166: 132-1332, 2005.

9. Hung C, Linn G, Chow YH, Kobayashi A, Mittelsteadt K, Altemeier WA, Gharib SA, Schnapp LM, Duffield JS: Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 188: 820-830, 2013.

10. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A: Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1: 71-81, 1994.

11. Reilkoff RA, Bucala R, Herzog EL: Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol. 11: 421-435, 2011.

12. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN: Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 166: 7558-7562, 2001.

13. Pilling D, Fan T, Huang D, Kaul B, Gomer RH: Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One 4: e7455, 2009.

14. Moore BB, Kolodskie JH, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB: CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 166: 675-684, 2005.

15. Moore BB, Murray L, Das A, Wilke CA, Herrygers AB, Toews GB: The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol 35: 175-181, 2006.

16. Aono Y, Ledford JG, Mukherjee S, Ogawa H, Nishioka Y, Sone S, Beers MF, Noble PW, Wright JR: Surfactant protein-D regulates effector cell function and fibrogenic lung remodeling in response to bleomycin injury. Am J Respir Crit Care Med 185: 526-536, 2012.

17. Makino H, Aono Y, Azuma M, Kishi M, Yokota Y, Kinoshita K, Takezaki A, Kishi J, Kawano H, Ogawa H, Uehara H, Izumi K, Sone S, Nishioka Y: Anti-fibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice. J Med Invest 60: 127-137, 2013.

18. Andersson-Sjöland A, de Alba CG, Nihlberg K, Becerril C, Ramírez R, Pardo A, Westergren-Thorsson G, Selman M: Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 40: 2129-2140, 2008.

19. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts BE, Farkas L, Dobranowski J, Boylan C, O’Byrne PM, Strieter RM, Kolb M: Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179: 588-594, 2009.

20. Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Santin-Janin H, Mulder GJ, Bartholmai B, Gupta R, Richeldi L: Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. JAMA 319: 2299-2307, 2018.

21. Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Moran D, Santin-Janin H, Aubin F, Mulder GJ, Gupta R, Richeldi L: Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respir Med 7: 657-664, 2019.

22. Kleveland KR, Velikhoff M, Yang J, Argawal M, Rippe RA, Moore BB, Kim KK: Fibrocytes are not an essential source of type I collagen during lung fibrosis. J Immunol 193: 5229-5239, 2014.

23. Aono Y, Kishi M, Yokota Y, Azuma M, Kinoshita K, Takezaki A, Sato S, Kawano H, Kishi J, Goto H, Uehara H, Izumi K, Nishioka Y: Role of platelet-derived growth factor/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis. Am J Respir Cell Mol Biol 51: 793-801, 2014.

24. Sato S, Shinohara S, Hayashi S, Morizumi S, Abe S, Okazaki H, Chen Y, Goto H, Aono Y, Ogawa H, Koyama K, Nishimura H, Kawano H, Toyoda Y, Uehara H, Nishioka Y: Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res 18: 172, 2017.

25. Garcia de Alba C, Buendia-Roldán I, Salgado A, Becerril C, Ramírez R, González Y, Checa M, Navarro C, Ruiz V, Pardo A, Selman M: Fibrocytes contribute to inflammation and fibrosis in chronic hypersensitivity pneumonitis through paracrine effects. Am J Respir Crit Care Med 191: 427-436, 2015.

26. Toyoda Y, Tabata S, Kishi J, Kuramoto T, Mitsuhashi A, Saio A, Kawano H, Goto H, Aono Y, Hanibuchi M,
Horikawa H, Nakajima T, Furukawa T, Sone S, Akiyama S, Nishioka Y: Thymidine phosphorylase regulates the expression of CXCL10 in rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheumatol 66: 560-568, 2014.

27. Azuma M, Nishioka Y, Aono Y, Inayama M, Makino H, Kishi J, Shono M, Kinoshita K, Uehara H, Ogushi F, Izumi K, Sone S: Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med 176: 1243-1250, 2007.

28. Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, Kuramoto T, Tabata S, Uehara H, Izumi K, Yoshida M, Kobayashi H, Takahashi H, Gotoh M, Kakiuchi S, Hanibuchi M, Yano S, Yokomise H, Sakiyama S, Nishioka Y: Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat Commun 6: 8792, 2015.

29. Sangaletti S, Tripodo C, Cappetti B, Casalini P, Chiodoni C, Piconese S, Santangelo A, Parenta M, Arioli I, Miotti S, Colombo MP: SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. Am J Pathol 179: 3000-3010, 2011.

30. Hartlapp I, Abe R, Saeed RW, Peng T, Voelter W, Bucala R, Metz CN: Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J 15: 2215-2224, 2001.

31. García-de-Alba C, Becerril C, Ruiz V, González Y, Reyes S, García-Alvarez J, Selman M, Pardo A: Expression of matrix metalloproteases by fibrocytes: possible role in migration and homing. Am J Respir Crit Care Med 182: 1144-1152, 2010.

32. Madala SK, Edukulla R, Schmidt S, Davidson C, Ikegami M, Hardie WD: Bone marrow-derived stromal cells are invasive and hyperproliferative and alter transforming growth factor-α-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 50: 777-786, 2014.

33. Ekert JE, Murray LA, Das AM, Sheng H, Giles-Komar J, Ryczyn MA: Chemokine (C-C motif) ligand 2 mediates direct and indirect fibrotic responses in human and murine cultured fibrocytes. Fibrogenesis Tissue Repair 4: 23, 2011.

34. Hayashi H, Kawakita A, Okazaki S, Murai H, Yasutomi M, Ohshima Y: IL-33 enhanced the proliferation and constitutive production of IL-13 and IL-5 by fibrocytes. Biomed Res Int 2014: 738625, 2014.

35. Galligan CL, Fish EN: Interleukin-34 Promotes Fibrocyte Proliferation. J Interferon Cytokine Res 37: 440-448, 2017.